These findings support the efficacy and safety of cagrilintide–semaglutide for weight management in individuals from east Asia with overweight or obesity, with or without type 2 diabetes.
The Lancet Diabetes & Endocrinology published a clinical update in Research Highlights on 17 Apr 2026. The item focuses on Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. Open the detail page to review the full original feed content.